Rapid Review : Part 1 by Shona Nag
Session 5 : Rapid Review : Part 1
Speaker :
Shona Nag
1. Expert Critique : Node-Positive Breast Ca: Door Opens to SLN After Neoadjuvant Chemo - False-negative rates lower with advances in surgical techniques (ACOSOG, Alliance Z1071 trial, The SN FNAC Study, SENTINA trial )
Author: Mateusz Opyrchal
Reference: Medpage Today ASCO Reading room
2. Axillary Lymph Node Dissection Can Largely Be Avoided in Breast Cancer (Z11 and Sound trial)
Author: Melissa Louise Pilewskie
Conference: 18th Annual Lynn Sage Breast Cancer Symposium Discussion
3. A model to predict axillary nodal pathologic complete response following neoadjuvant chemotherapy for breast cancer
Author: O Kantor
Conference: 2016 ASCO Annual Meeting, Abstract1047
4. Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial
Author: D Hyman
Conference: 2016 SABCS PD2-08
5. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
Author: Kala Visvanathan
Reference: J Clin Oncol. 2016 Nov 21
6. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial
Author: J Balmana
Conference: 2016 ESMO 223O
7. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials
Author: Clavarezza M
Reference: Clin Cancer Res; 22(18); 4594-603
8. Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer - the UK EPHOS-B trial (CRUK/08/002)
Author: N. Bundred
Conference: 2016 EBCC 6LBA
9. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
Reference: Lancet Oncol. 2016 Dec 6. pii: S14702045 (16) 30631-3
10. Original Investigation: RNA Sequencing to Predict Response to Neoadjuvant Anti HER2 Therapy.A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Author: Debora Fumagalli
Reference: JAMA Oncol. 2016 Sep 29
11. Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial
Author: Amir Sonnenblick
Reference: J Natl Cancer Inst. 2016 Apr 20;108(8)
12. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases
Author: Nolan Priedigkeit
Reference: JAMA Oncol. 2016 Dec 7
13. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1 associated and sporadic triple-negative breast cancer
Author: Nadine M. Tung
Reference: npj Breast Cancer 2, Article number:16002(2016)
14. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC
Author: Joel S. Parker
Reference: J Clin Oncol 33, 2015 (suppl; abstr 1083)
15. Lack of Androgen Receptor Protein May Contribute to Racial Disparities in Triple Negative Breast Cancer Outcomes
Author: Ritu Aneja
Conference: AACR Abstract B12
16. A phase II, open-label, multicentre, translational study for biomarkers of eribulin mesylate: evaluation of the utility of monitoring epithelial-to-mesenchymal transition (emt) markers on tumour cells in the malignant plural effusion of patients with metastatic breast cancer (expect-study)
Author: Watanabe
Conference: 2016 SABCS OT1-01-01
17. Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy
Author: Priyanka Sharma
Conference: 2016 ASCO Annual Meeting, Abstract 1015
18. BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer
Author: K Rhiem
Conference: 2016 ASCO Annual Meeting, Abstract 1090
19. Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer
Author: Chiun-Sheng Huang
Conference: 2016 ASCO Annual Meeting, Abstract 1003
20. Randomized, double blind trial to evaluate the safety and efficacy of metformin vs placebo plus neoadjuvant chemotherapy in locally advanced breast cancer
Author: C Arce-Salinas
Conference: 2016 ASCO Annual Meeting, Abstract 579n
21. A phase II, multicentre, randomised trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy
Author: Park et al
Conference: 2016 SABCS OT1-01-12
22. PAINTER: Evaluation of eribulin tolerability and correlation between a set of Polymorphisms and neuropathy in patients with metastatic breast cancer
Author: La Verde
Conference: 2016 SABCS OT1-01-05
23. Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study
Author: Nis P. Suppli
Reference: JCO,November 14, 2016
24. A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer
Author: Husam Abdel-Qadir
Conference: JAMA Cardiology,2016 Oct 12
25. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis
Author: Charles Guenancia
Reference: J Clin Oncol. 2016 Sep 10;34(26):3157 65n
26. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy
Author: D Zardavas
Reference: J. Clin. Oncol 2016 Oct 23
27. The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: A population study
Author: Hart A.Goldhar
Reference: JNCI J Natl cancer Inst (2016) 108(1)
28. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node negative ERBB2-positive breast cancer
Author: C Dang
Reference: JAMA Oncol. 2016 Jan;2(1):29-36
29. Effect of Temporary Ovarian Suppression on Chemotherapy-Induced Amenorrhea, Pregnancy, and Outcome
Author: Pamela N. Munster
Reference: JAMA Oncol. 2016 Aug 1;2(8):1089-90
30. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline
Author: Rugo HS
Reference: J Oncol Pract. 2016 Jun;12(6):583-7
31. Do all patients with advance HER2 positive breast cancer need upfront - cemo when receiving trastuzumab ? Randamized phase III trial SAKK 22/29
Author: Pagani O
Reference: Ann Oncol. 2016 Dec 19. pii : mdw622. doi:10.1093/annonc/mdw622